Results 121 to 130 of about 98,415 (200)

Glucagon-Like Peptide-1 Receptor Agonist Switching and Treatment Persistence in Adults Without Diabetes.

JAMA Netw Open
Xie L, Anazco D, Chancay AH, Mathew MS, Francis JM, Almandoz JP, Messiah SE.   +6 more
europepmc   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Knee Arthroplasty Outcomes. [PDF]

Indian J Orthop
Zaffar H, Imran MA, Rushd F.
europepmc   +1 more source

Adverse events administering glucagon-like peptide-1 receptor agonists: a cross-sectional study. [PDF]

Health Aff Sch
Mattingly TJ, Duru EE, Conti RM.
europepmc   +1 more source

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. [PDF]

Diabetes Obes Metab
Vilsbøll T, Stellfeld M, Aroda VR, Dandanell S, David JP, Kristiansen CTP, Rasmussen S, Roberts FL, Hegedüs L.   +8 more
europepmc   +1 more source

Thyroid Cancer Risk in Patients With Type 2 Diabetes Taking Glucagon-Like Peptide 1 Receptor Agonists. [PDF]

OTO Open
Sciscent BY, Eberly HW, Lorenz FJ, Goldrich D, Goyal N, Goldenberg D.   +5 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis. [PDF]

Cureus
Nashwan AJ.
europepmc   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. [PDF]

Cureus
Graczyk NA, Bisschops J.
europepmc   +1 more source

Glucagon-like peptide-1 receptor (GLP1R; GLP-1R) [PDF]

Science-Business eXchange, 2011
openaire   +1 more source

Glucagon-like Peptide-1 Receptor Agonists and Ocular Disease: Mechanisms, Evidence and Therapeutic Perspectives. [PDF]

Int J Mol Sci
Gong X, Örge FH.
europepmc   +1 more source